Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
The American Journal of Gastroenterology|April 22, 2015
Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin UsersC Sostres, P Carrera-Lasfuentes, R Benito, et al.Alimentary Pharmacology & Therapeutics|July 19, 2012
Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR)A Lanas, J L Goldstein, F K L Chan, et al.International Journal of Colorectal Disease|May 13, 2021
False-positive fecal immunochemical test results in colorectal cancer screening and gastrointestinal drug useM J Domper Arnal, S García Mateo, S Hermoso-Durán, et al.Genes and Immunity|September 15, 2006
TGFB1 gene polymorphisms: their relevance in the susceptibility to Helicobacter pylori-related diseasesM A Garcia-Gonzalez, M Strunk, E Piazuelo, et al.Lancet (London, England)|October 6, 1998
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion PreventionC J Hawkey, Z Tulassay, L Szczepanski, et al.Alimentary Pharmacology & Therapeutics|August 4, 2011
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trialsJ L Goldstein, F K L Chan, A Lanas, et al.Journal of Thrombosis and Haemostasis : JTH|June 20, 2014
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug actionP Patrignani, S Tacconelli, E Piazuelo, et al.Clinical Pharmacology and Therapeutics|February 1, 2017
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal CancerP Patrignani, A Sacco, C Sostres, et al.Cardiovascular Drugs and Therapy|February 19, 2013
Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including complianceN L de Groot, H G M van Haalen, B M R Spiegel, et al.Alimentary Pharmacology & Therapeutics|September 5, 2007
Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagusA Lanas, J Ortego, F Sopeña, et al.Pageof 10